FindTrial
Sign In

Carboplatin AUC 6

DRUG4 trials

Sponsors

University of Massachusetts, Worcester, Merck Sharp & Dohme LLC, Spanish Lung Cancer Group, Cullinan Therapeutics Inc.

Conditions

Advanced Solid TumorCarcinoma, Non-Small-Cell LungLung CancerNSCLCNeoplasmsNon Small Cell Lung Cancer

Phase 1

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
TerminatedNCT00424840
University of Massachusetts, WorcesterLung Cancer
Start: 2006-06-30End: 2014-03-31Updated: 2019-02-01
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
CompletedNCT02862457
Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung, Neoplasms
Start: 2016-08-23End: 2020-11-20Updated: 2022-08-19
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Active, not recruitingNCT05117476
Cullinan Therapeutics Inc.Advanced Solid Tumor, NSCLC
Start: 2021-10-29End: 2026-06-30Target: 440Updated: 2025-11-24

Phase 2

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
CompletedNCT03081689
Spanish Lung Cancer GroupNon Small Cell Lung Cancer
Start: 2017-04-15End: 2023-10-18Updated: 2024-12-04

Related Papers

Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.
2026-03-10
Abstract B020: NETosis-specific clipped histone H3 is a novel biomarker of response to neoadjuvant chemo-immunotherapy in resectable lung cancer
Cancer Immunology Research2025-09-24
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
OncoImmunology2025-06-051 citations
Abstract 4542: B cells mediate antitumor immune response and predict pathological response in locally advanced NSCLC patients treated with perioperative chemoimmunotherapy (NADIM trials)
Cancer Research2025-04-21
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
2024-10-1437 citations
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
Journal for ImmunoTherapy of Cancer2024-10-0111 citations
Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.
Journal of Clinical Oncology2024-06-011 citations
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
2024-03-264 citations
Abstract 5297: CLN-619, a clinical stage MICA/B-specific hIgG1 monoclonal antibody, engages multiple immune effector cells to promote anti-tumor activity
Cancer Research2024-03-221 citations
194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
Regular and Young Investigator Award Abstracts2023-10-31
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
Journal of Clinical Oncology2023-06-011 citations
Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).
Journal of Clinical Oncology2023-06-01
Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
Frontiers in Oncology2023-05-1510 citations
1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity
Regular and Young Investigator Award Abstracts2022-11-011 citations
Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer.
Journal of Clinical Oncology2022-06-013 citations
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-011 citations
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology2022-05-16318 citations
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Clinical Cancer Research2021-08-1061 citations
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer2021-08-0112 citations
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
Clinical and Translational Medicine2021-07-0153 citations

10 more papers not shown